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Therapeutic exon skipping for dysferlinopathies?
Annemieke Aartsma-Rus*,1, Kavita HK Singh1, Ivo FAC Fokkema1, Ieke B Ginjaar1, Gert-Jan van Ommen1,
Johan T den Dunnen1 and Silve `re M van der Maarel1
Antisense-mediated exon skipping is a promising therapeutic approach for Duchenne muscular dystrophy (DMD) currently tested
in clinical trials. The aim is to reframe dystrophin transcripts using antisense oligonucleotides (AONs). These hide an exon from
the splicing machinery to induce exon skipping, restoration of the reading frame and generation of internally deleted, but
partially functional proteins. It thus relies on the characteristic of the dystrophin protein, which has essential N- and C-terminal
domains, whereas the central rod domain is largely redundant. This approach may also be applicable to limb-girdle muscular
dystrophy type 2B (LGMD2B), Myoshi myopathy (MM) and distal myopathy with anterior tibial onset (DMAT), which are caused
by mutations in the dysferlin-encoding DYSF gene. Dysferlin has a function in repairing muscle membrane damage. Dysferlin
contains calcium-dependent C2 lipid binding (C2) domains and an essential transmembrane domain. However, mildly affected
patients in whom one or a large number of DYSF exons were missing have been described, suggesting that internally deleted
dysferlin proteins can be functional. Thus, exon skipping might also be applicable as a LGMD2B, MM and DMAT therapy. In this
study we have analyzed the dysferlin protein domains and DYSF mutations and have described what exons are promising targets
with regard to applicability and feasibility. We also show that DYSF exon skipping seems to be as straightforward as DMD exon
skipping, as AONs to induce efﬁcient skipping of four DYSF exons were readily identiﬁed.
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INTRODUCTION
Limb-girdle muscular dystrophy type 2B (LGMD2B), Myoshi
myopathy (MM) and distal myopathy with anterior tibial onset
(DMAT) are autosomal recessive allelic muscle diseases caused by
mutations in the dysferlin-encoding DYSF gene, leading to severely
reduced or complete absence of the dysferlin protein.1–3 Most patients
have small mutations: stop- or frameshift mutations lead to prema-
turely truncated proteins, whereas missense mutations generally
affect protein stability.4 Over 100 different mutations have been
reported in the Leiden Open Variation Database for almost 200
patients (www.dmd.nl). As there is currently no treatment for the
‘dysferlinopathies’, lack of dysferlin leads to progressive loss of tissue
and function in the muscles of the limbs and girdle.5
The dysferlin protein is expressed in many tissues, but most
abundantly in the heart and skeletal muscle.5 In the latter, the protein
is located at the plasma membrane and in cytoplasmic vesicles.6 It is
thought that dysferlin has a function in vesicle trafﬁcking and
membrane patch fusion repair in muscle cells.5 Loss of dysferlin
compromises skeletal muscle membrane repair and leads to progressive
loss of muscle ﬁbers.6 The protein has different domains (Figure 1).
The ENSEMBL database predicts six or seven calcium-dependent C2
lipid-binding (C2) domains, a transmembrane domain and multiple
‘fer’ and ‘dysf’ domains. The C2 domains probably mediate calcium-
dependent vesicle fusion with the plasma membrane, whereas the
transmembrane domains anchor the protein to the plasma mem-
brane.5 The fer and dysf domains have as yet an unknown function.4
It is likely that parts of the dysferlin protein are redundant. The ﬁrst
indication for this is a ﬁnding by Sinnreich et al7 that the mother of
two LGMD2B patients turned out to be a compound heterozygote
rather than a carrier. One of the alleles contained a mutated branch-
point in intron 31, leading to skipping of exon 32. As exon 32 skipping
does not disrupt the open reading frame, this resulted in a slightly
shorter but apparently partly functional dysferlin protein at levels that
were 10% of wild-type levels. The patient had only very mild proximal
muscle weakness, elevated serum creatine kinase levels and was still
ambulant at age 70. In contrast, her severely affected daughters were
homozygous for a null mutation and had no dysferlin protein. In
addition, a mildly affected patient has been presented with a dysferlin
containing only the ﬁnal two C2 and the transmembrane domains.8
This patient was ambulant without a cane at age 41. Further proof for
the functionality of this protein came from its proper location at the
sarcolemma and the delivery of a gene encoding this ‘minidysferlin’
into a dysferlin-negative mouse model through an adeno-associated
viral vector. This resulted in detectable levels of the mini-dysferlin
protein and an improved phenotype.
Thus, it is possible that bypassing dysferlin mutations could lead to
more stable, (partly) functional dysferlin proteins and would therefore
have therapeutic potential. A way to achieve this is the modulation of
dysferlin pre-mRNA splicing using antisense oligonucleotides (AONs)
or antisense sequences, which hide target exons from the splicing
machinery, such that they are not included into the ﬁnal mRNA
(‘exon skipping’) (Figure 2). Initial proof of concept was recently
shown in control and patient-derived cells, were exon 32 skipping was
induced by either AONs or through an a modiﬁed U7 snRNP inwhich
the original antisense sequence was replaced by the target antisense
sequence.9
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www.nature.com/ejhgIn fact, the exon skipping approach is currently the most promising
therapeutic approach for Duchenne muscular dystrophy (DMD).10
This disease is caused by a complete loss of functional dystrophin
due to mutations that disrupt the open reading frame of the DMD
gene.11 Similar to dysferlin, dystrophin contains essential and less
essential domains, underlined by the ﬁnding that patients with
in-frame mutations in the redundant central domain suffer from a
milder disease called Becker muscular dystrophy.12–14 AON-medicated
exon skipping for DMD patients aims to restore the open reading frame,
to allow the production of a partly functional protein and conversion of
the severe DMD into a milder BMD phenotype. This approach was
pioneered in our lab and by colleagues in Japan, Australia and the
United Kingdom10,15–18 and is currently in phase I/II clinical trials.19,20
In this study we will analyze what DYSF exons might be suitable
targets for antisense-mediated exon skipping and what are less or
nonsuitable targets, based on the protein encoding domains and
reported mutations. We also show that using our guidelines estab-
lished after retrospective analysis of our set of DMD AONs, AONs to
induce DYSF exon skipping can be readily identiﬁed.
METHODS
Database
Mutations as reported on 8 May 2009 in the DYSF LOVD database
(www.dmd.nl) were analyzed.
AONs
AON design was based on our guidelines for DMD exons and focused on
targeting partiallyopen secondary RNA structures (predicated by m-fold21), the
presence of predicted RESCUE-ESE and SC35 and the absence of predicted
Tra2b sites (using the human splicing ﬁnder22) and favorable binding
energy.21,23 All AONs (Table 1) target exon-internal sequences and consist of
2¢-O-methyl RNA with a full-length phosphorothioate backbone and were
manufactured by Eurogentec (Seraing, Belgium).
Cell culture and transfection
Human control myoblasts were cultured and differentiated as described
previously.24 AONs were transfected at a 500nM concentration, using 2.5ml
polyethyleneimine (MBI-Fermentas, Leon-Rot, Germany) per mg AON accord-
ing to the manufacturer’s instructions. An unrelated 5-ﬂuorescein-labeled AON
targeting exon 45 of the dystrophin gene was used to conﬁrm the efﬁciency of
transfection (490%).
RNA analysis
RNA was isolated at 428h after transfection using RNA-Bee (Campro
Scientiﬁc, Veenendaal, the Netherlands) according to the manufacturer’s
instruction. An RT-PCR was performed with random hexamer primers, as
described.25 Primers ﬂanking the targeted exons (sequence on request) were
used to amplify the cDNA as described previously for dystrophin,24 but using a
single PCR for 35 cycles. Skip products were analyzed by sequencing analysis as
described.24
RESULTS AND DISCUSSION
Exon skipping for dysferlin
Obviously, not every DYSF exon can be skipped without consequence
for dysferlin function. First, if the skipped exon is out-of-frame (ie, the
length is not divisible by three), this will result in a disruption of the
open reading frame and a prematurely truncated protein. Thus, either
in-frame exons, or a combination of out-of-frame exons that together
maintain the reading frame, are valid targets (Figure 3 and Table 2).
Second, as mentioned, dysferlin contains several domains, and
although only limited information is available about their function
and essentiality, several things can be learned about these domains
from mutations found in patients and animal models. The very mildly
affected individual skipping exon 32 suggests that, although exon 32
encodes the fourth C2 domain, a dysferlin without this exon is highly
functional.7 Thus, apparently the fourth C2 domain is (at least
partially) redundant. In contrast, the ﬁnal C2 domain is likely essential
for functionality, as a mouse model SJL/J (SJL-Dysf) with a splice site
mutation resulting in the in-frame skipping of exon 45, leading to the
omission of the last part of the ﬁnal C2 domain, has a dystrophic
phenotype.26,27 The mild patient producing a dysferlin consisting of
only the last C2 and the transmembrane domains could suggest that
the other four C2 domains are redundant. However, whereas this
corresponding mini-dysferlin protein is apparently relatively stable,
this does not necessarily hold for all dysferlins with mutations before
exon 44, and seems to be an exception rather than a rule.4
Third, only internal exons can be skipped, and thus exons 1 and 55
are invalid targets. Additional exons that provide invalid targets are
in-frame exons 19, 25 and 49 for which splice site mutations resulting
in exon skipping (conﬁrmed by RT-PCR) have been found in
LGMD2B and MM patients (4 and the LOVD DYSF database).
Mutations that may affect splicing (ie, located at or close to the splice
sites) have been identiﬁed in MM and LGMD2B patients for exons 24,
30, 32, 34, 37 and 41. However, the mutations were found at the DNA
level and have not been conﬁrmed at the RNA level.
On the basis of this information, exons can be subdivided into
suitable and less suitable and impossible candidates (Table 2).
Although there are no real mutational hotspots in the DYSF gene,
some exons contain more mutations than others and the skipping of
these exons would thus be applicable to larger groups of patients (see
Figure 1 Dysferlin domains relative to DYSF exons. Dysferlin contains six or seven calcium-dependent C2 lipid binding domains (C2), a transmembrane
domain (T), a ferl domain (L), FerA and FerB domains (A and B, respectively) and Dysf_N and Dysf_C domains (N and C, respectively). The C2 and
transmembrane domains have a function in membrane repair. The function of other domains is yet unknown.
Figure 2 Antisense-mediated exon skipping. Left panel: in this example, a
mutation within exon 32 results in a premature stop codon (indicated by the
transition of black to white in the pre-mRNA (top) and mRNA (middle),
which leads to a prematurely truncated protein (bottom). Right panel: when
antisense oligonucleotides (AON) targeting exon 32 are used, they will
hybridize to this exon, thus hiding it from the splicing machinery, resulting
in the skipping of this exon. As exon 32 in in-frame (its length is divisible
by three), skipping will not disrupt the reading frame (the mRNA becomes
black in the middle panel) and a full-length protein, which misses a little bit
in the middle, can be generated (bottom).
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17 and 35.
Prioritizing DYSF exons
Obviously, when assessing the feasibility of DYSF exon skipping,
one should start with the most straightforward approach (single
exon skipping), targeting those exons that are most likely or have
been conﬁrmed to be redundant. This includes exons 17, 32, 35, 36
and 42. As no mutations have been reported yet for exons 17 and 35,
initial focus should not be on those exons. Exons 34 and 41 are
in-frame and theoretically eligible targets as they encode no domains
or the redundant C2 domain. However, putatively causal mutations
that induce skipping of these exons have been identiﬁed at the DNA
level. Thus, exons 32 and 36 seem to be prime candidates, with the
other mentioned exons close seconds.
As skipping two or three exons simultaneously (double and triple
exon skipping, respectively) is feasible for DMD,25,28 it is probably also
feasible for DYSF. The only combination of adjacent exons that
together is in-frame (ie, the total number of nucleotides is divisible
by three) while not encoding any domains is 20+21, whereas there are
also some in-frame three exon combinations possible (18+19+20 and
31+32+33).
Finally, in-frame exons 24 and 30 encode the FerB and Dysf-C2
domains, the additional domains for which the essentiality for
dysferlin function is still unknown. Thus, exon skipping for these
exons might be beneﬁcial. All other exons or exon combinations
encode C2 domains or the transmembrane domain and are very likely
to interfere with protein function, and should have a lower priority
(Table 2).
Skipping the highest priority exons (rank 1–3) could be beneﬁcial
for over 20% of all dysferlinopathy patients (Table 2). This is probably
a slight overestimation, as a number of patients may be counted
twice as they have mutations in two eligible exons (compound
heterozygotes). The recessive nature of dysferlinopathies poses certain
obstacles that are not present in the X-recessive DMD. For instance, a
patient can have mutations in exons 32 and 30. When targeting both
exons, it is likely that in most transcripts both exons will be skipped,
as double exon skipping is usually quite efﬁcient.25 This is probably
not beneﬁcial. However, levels of B10% are apparently sufﬁcient to
prevent disease in the aforementioned patient who lacked exon 32,7
suggesting that it is not essential to correct both mutations and/or
restore dysferlin levels to 100%. Therefore, it may be better to target
just one mutated exon (eg, exon 32), which will result in skipping of
the unintended exon (wild-type exon 32 in the exon 30 mutated
transcript), but also of the intended exon (mutated exon 32). The
intended exon skipping will result in functional dysferlin, whereas the
unintended exon skipping will not further worsen the disease as a
non-functional dysferlin (due to the exon 30 mutation) is now
converted in another non-functional dysferlin (exon 30 mutation
and exon 32 skip).
Feasibility of DYSF exon skipping
Antisense-mediated skipping of DMD exons is very straightforward;
AONs to skip each exon have been identiﬁed.23,29,30 To assess whether
exon skipping can be as easily achieved for DYSF exons, we designed
two AONs for each exon targeting DYSF exons 19, 24, 30 and 34, and a
single AON targeting the small exon 32, using our previously
identiﬁed AON design guidelines.23,29 AONs were transfected in
differentiated human control myoblasts. RT-PCR analysis revealed
that six AONs were effective and induced skipping of exons 19, 24, 30
and 34 (Figure 4). Exon skipping levels varied from 17% (exon 34) to
96% (exon 30). Notably, some spontaneous skipping (alternative
splicing) of exon 30 was observed in non-treated cells at low levels
(10%). The single exon 32 AON was not effective (Figure 4), but exon
32 skipping can be induced by other AONs.9
For some DMD exons, skipping of additional adjacent exons was
observed, either exclusively or in addition to skipping of the targeted
exon only.29 This is unwanted for dysferlinopathies as the skipping of a
number of in-frame exons leads to non-functional dysferlins (Table 2).
However, skipping of additional exons was not observed for the four
dysferlin exons targeted in this study (data not shown). Furthermore,
the skipping of multiple exons happens only occasionally for DMD
exons and even when it occurs the amount of transcripts with a single
skip often vastly exceeds the amount of transcripts in which more
exons are skipped consecutively.
CONCLUDING REMARKS
In conclusion, exon skipping poses a putative strategy for dysferlino-
pathies, although some exons are arguably more eligible than others. It
should be pointed out that the ideal target mutations are homozygous
mutations in an eligible target exon, as in this case skipping the
targeted exons on both alleles could be therapeutic. However, as 10%
of dysferlin levels seem to be sufﬁcient to improve the phenotype,7 this
approach is also promising for heterozygous mutations. Skipping of
only the mutated exon here could be potentially therapeutic, whereas
skipping of the non-target allele is not. Nevertheless, this could still
lead to dysferlin levels of up to 50%. Fortunately, skipping DYSF exons
seems to be straightforward. It is known that some mutations can
cause misfolding of dysferlin and retention in the endoplasmatic
reticulum.31 This is also a possibility for the internally deleted
dysferlins. Therefore, studies in patient-derived cells are needed, as
only these will be able to conﬁrm whether other internally deleted
dysferlins are functional and located properly.
Table 1 AONs used in this study
AON name Sequence Exon
H19DYSF1 5¢-GAAGCCGGCCACGAUAAGCC-3¢ 19
H19DYSF2 5¢-CCUUCUGUUCACUGUGCUCC-3¢ 19
H24DYSF1 5¢-GCAUCCAGAUGACGAUGUCCG-3¢ 24
H24DYSF2 5¢-GCUUCCCACAAUUCUUGCCA-3¢ 24
H30DYSF1 5¢-CCGUCUUCUCCAGUGGCUCC-3¢ 30
H30DYSF2 5¢-CGGCGGAAGGCAUCUGUCUUG-3¢ 30
H32DYS1 5¢-UCCGUUCCAGACUCGGUUCAC-3¢ 32
H34DYSF1 5¢-CGACGGCUGGCUGCCCCUCGUC-3¢ 34
H34DYSF2 5¢-GCAGCGUAGAUGGUAGCGGU-3¢ 34
Figure 3 Dysferlin exons. In-frame exons are depicted in white, out-of-frame
exons in black. Exons or combinations of exons can be skipped without
disrupting the reading frame, when the resulting ends ﬁt (eg, exons 39 and
40 can be skipped, as the end of exon 38 ﬁts to the beginning of exon 41).
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Exon  Domain  In frame  Combination
1 Remarks  Applicability
2 Priority
3
1 C2-1  no no 0% NA
2 C2-1  no 2, 3, 4 and 5  1.8%  9
3 C2-1  no 3 and 4  2.1%  8
4 C2-1  no 3 and 4  1.3%  8
5 C2-1  no 5 and 6  4.2%  8
6 None  no 5 and 6  6.1%  8
7 C2-2  yes 1.6%  7
8 C2-2  yes 2.9%  7
9 C2-2  yes 1.8%  7
10 C2-2 & FerL  no 10 and 11  1.6%  8
11 C2-2 & FerL  no 10 and 11  0.5%  8
12 C2-3  no 12 and 13  16.6% 8
13 C2-3  no 12 and 13  4.5%  8
14 C2-3  yes 14 0.3%  7
15 C2-3  no 15 and 16  2.6%  9
16 C2-3  no 15 and 16  1.1%  9
17 C2-3  yes
No mutations reported 
Alternatively spliced  0%
1
18 none no 18, 19 and 20  4.0%  3
19 none yes Skip pathogenic   5.8%  NA
20 none no 20 and 21  5.3%  2
21 none no 20 and 21  1.8%  2
22 FerA  no 22 and 23  0.8%  6
23 FerA & FerB  no 22 and 23  3.2%  6
24 FerB  yes Skip possibly pathogenic  4.5%  5
25 FerB  yes Skip pathogenic  3.7%  NA
26 Dysf-N-1  no 26 and 27  1.8%  6
27 Dysf-N-2  no 26 and 27  6.6%  6
28 Dysf-N-2  no 28 and 29  5.3%  6
29 Dysf-C-1  no 28 and 29  6.6%  6
30 Dysf-C-2  yes Skip possibly pathogenic  8.4%  5
31 None  31, 32, 33  no 3.7%  3
32 C2-4  yes Skip does not disturb function  4.0%  1
33 C2-4  31, 32, 33  no 2.4%  3
34 C2-4  yes Skip possibly pathogenic  4.5%  4
35 None  yes No mutations reported  0% 1
36 None  yes 0.8%  1
37 C2-5  yes Skip possibly pathogenic  3.7%  7
38 C2-5  yes 3.7%  7
39 C2-5  no 39 and 40  3.2%  8
40 none no 39 and 40  0.3%  8
41 none yes Skip possibly pathogenic  3.4%  4
42 none yes 0.8%  1
43 C2-6  yes 4.2%  7
44 C2-6  no 44, 45, 46 and 47  11.9% 9
45 C2-6  yes Skip pathogenic in mouse  5.3%  NA
46 none no 46, 47 and 48  2.4%  9
47 none no 46, 47 and 48  2.1%  9
48 C2-7  no 46, 47 and 48  1.1%  9
49 C2-7  yes Skip pathogenic  4.7%  NA
50 C2-7  no 50, 51, 52 and 53  3.7%  9
51 C2-7  no 51 and 52  5.8%  8
52 C2-7  no 51 and 52  3.7%  8
53 none no 53 and 54  5.0%  8
54 TMB  no 53 and 54  3.4%  8
55 TMB  no not applicable  1.6%  NA
aIndicates what combination of exons would be in-frame.
bThe applicability is based on the mutations reported in the DYSF database (www.dmd.nl). As most patients have heterozygous mutations, the total applicability is 4100%.
cIndicates what exons make good targets on a scale of 1–9, where 1 is optimal and 9 least optimal; NA is for unsuitable exons.
Exon skipping for dysferlinopathies?
AA a r t s m a - R u set al
892
European Journal of Human GeneticsCONFLICT OF INTEREST
AA-R and G-JBvO are employees of Leiden University Medical Center
and coinventors on patent applications for antisense sequences and
exon-skipping technology.
ACKNOWLEDGEMENTS
AAR is funded by grants from ZonMw (The Netherlands) and the Duchenne
Parent Project (The Netherlands) and the FP6 TREAT-NMD network of
excellence.
1 Liu J, Aoki M, Illa I et al: Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi
myopathy and limb girdle muscular dystrophy. Nat Genet 1998; 20:3 1 – 3 6 .
2 Bashir R, Britton S, Strachan T et al: A gene related to Caenorhabditis elegans
spermatogenesis factor fer-1 is mutated in limb-girdle muscular dystrophy type 2B.
Nat Genet 1998; 20:3 7 – 4 2 .
3 Illa I, Serrano-Munuera C, Gallardo E et al: Distal anterior compartment myopathy: a
dysferlin mutation causing a new muscular dystrophy phenotype. Ann Neurol 2001;
49: 130–134.
4 Therrien C, Dodig D, Karpati G, Sinnreich M: Mutation impact on dysferlin inferred from
database analysis and computer-based structural predictions. JN e u r o lS c i2006; 250:
71–78.
5 Bansal D, Campbell KP: Dysferlin and the plasma membrane repair in muscular
dystrophy. Trends Cell Biol 2004; 14: 206–213.
6 Bansal D, Miyake K, Vogel SS et al: Defective membrane repair in dysferlin-deﬁcient
muscular dystrophy. Nature 2003; 423: 168–172.
7 Sinnreich M, Therrien C, Karpati G: Lariat branch point mutation in the dysferlin gene
with mild limb-girdle muscular dystrophy. Neurology 2006; 66: 1114–1116.
8 Krahn M, Wein N, Lostal W et al: Partial functionality of a mini-dysferlin molecule
identiﬁed in a patient affected with moderately severe primary dysferlinopathy.
Neuromuscul Disord 2008; 18:7 8 1 .
9 Wein N, Avril A, Bartoli M et al: Efﬁcient bypass of mutations in dysferlin deﬁcient
patient cells by antisense-induced exon skipping. Hum Mutat 2009, e-pub ahead of
print 1 December 2009.
10 van Ommen GJ, van Deutekom J, Aartsma-Rus A: The therapeutic potential of
antisense-mediated exon skipping. Curr Opin Mol Ther 2008; 10: 140–149.
11 Hoffman EP, Brown Jr RH, Kunkel LM: Dystrophin: the protein product of the
Duchenne muscular dystrophy locus. Cell 1987; 51: 919–928.
12 Hoffman EP, Fischbeck KH, Brown RH et al: Characterization of dystrophin in muscle-
biopsy specimens from patients with Duchenne’s or Becker’s muscular dystrophy.
NE n g lJM e d1988; 318: 1363–1368.
13 Koenig M, Monaco AP, Kunkel LM: The complete sequence of dystrophin predicts a
rod-shaped cytoskeletal protein. Cell 1988; 53:2 1 9 – 2 2 6 .
14 Monaco AP, Bertelson CJ, Liechti-Gallati S, Moser H, Kunkel LM: An explanation for
the phenotypic differences between patients bearing partial deletions of the DMD
locus. Genomics 1988; 2:9 0 – 9 5 .
15 Dunckley MG, Manoharan M, Villiet P, Eperon IC, Dickson G: Modiﬁcation of splicing in
the dystrophin gene in cultured Mdx muscle cells by antisense oligoribonucleotides.
Hum Mol Genet 1998; 7: 1083–1090.
16 Takeshima Y, Wada H, Yagi M et al: Oligonucleotides against a splicing enhancer
sequence led to dystrophin production in muscle cells from a Duchenne muscular
dystrophy patient. Brain Dev 2001; 23:7 8 8 – 7 9 0 .
17 Wilton SD, Lloyd F, Carville K et al: Speciﬁc removal of the nonsense mutation from the
mdx dystrophin mRNA using antisense oligonucleotides. Neuromuscul Disord 1999; 9:
330–338.
18 van Deutekom JC, Bremmer-Bout M, Janson AA et al: Antisense-induced exon skipping
restores dystrophin expression in DMD patient derived muscle cells. Hum Mol Genet
2001; 10: 1547–1554.
19 Muntoni F, Bushby KD, van Ommen G: 149th ENMC international workshop and 1st
TREAT-NMD workshop on: ‘planning phase i/ii clinical trials using systemically
delivered antisense oligonucleotides in Duchenne muscular dystrophy’. Neuromuscul
Disord 2008; 18: 268–275.
20 van Deutekom JC, Janson AA, Ginjaar IB et al: Local dystrophin restoration with
antisense oligonucleotide PRO051. NE n g lJM e d2007; 357: 2677–2686.
21 Zuker M: Mfold web server for nucleic acid folding and hybridization prediction.
Nucleic Acids Res 2003; 31: 3406–3415.
22 Desmet FO, Hamroun D, Lalande M, Collod-Beroud G, Claustres M, Beroud C: Human
splicing ﬁnder: an online bioinformatics tool to predict splicing signals. Nucleic Acids
Res 2009; 37:e 6 7 .
23 Aartsma-Rus A, van Vliet L, Hirschi M et al: Guidelines for antisense oligonucleotide
design and insight into splice-modulating mechanisms. Mol Ther 2008.
24 Aartsma-Rus A, Janson AA, Kaman WE et al: Therapeutic antisense-induced exon
skipping in cultured muscle cells from six different DMD patients. Hum Mol Genet
2003; 12: 907–914.
25 Aartsma-Rus A, Janson AA, Kaman WE et al: Antisense-induced multiexon skipping
for duchenne muscular dystrophy makes more sense. Am J Hum Genet 2004; 74:
83–92.
26 Vaﬁadaki E, Reis A, Keers S et al: Cloning of the mouse dysferlin gene and
genomic characterization of the SJL-Dysf mutation. NeuroReport 2001; 12:
625–629.
Figure 4 RT-PCR analysis of AON-treated control cell cultures. AONs 19–2, 24–1, 24–2, 30–1, 30–2 and 34–1 are effective, whereas 19–1, 32, 34–2 and
C (a control AON targeting the DMD (dystrophin) gene) are not. Correct exon skipping was conﬁrmed using sequence analysis (data not shown). No exon 19,
24, 32 or 34 skipping could be observed in nontreated (NT) cells, whereas for exon 30 low levels of physiological skipping were observed. AON treatment
signiﬁcantly increased these levels from o10 to 490%. Skipping percentages using Lab-on-a-chip (Agilent, Amstelveen, the Netherlands) are indicated
below each skip. Note that the intensity of the skip products is lower, due to the smaller fragment length (our efﬁciency assessment corrects for this).– R T
and H2O are negative controls. M is size marker.
Exon skipping for dysferlinopathies?
A Aartsma-Rus et al
893
European Journal of Human Genetics27 Bittner RE, Anderson LV, Burkhardt E et al: Dysferlin deletion in SJL mice (SJL-Dysf)
deﬁnes a natural model for limb girdle muscular dystrophy 2B. Nat Genet 1999; 23:
141–142.
28 Aartsma-Rus A, Janson AA, van Ommen GJ, van Deutekom JC: Antisense-induced exon
skipping for duplications in Duchenne muscular dystrophy. BMC Med Genet 2007;
8:4 3 .
29 Aartsma-Rus A, Winter CL, Janson AAM et al: Functional analysis of 114 exon-internal
AONs for targeted DMD exon skipping: indication for steric hindrance of
SR protein binding sites. Oligonucleotides 2005; 15: 284–297.
30 Wilton SD, Fall AM, Harding PL, McClorey G, Coleman C, Fletcher S: Antisense
oligonucleotide-induced exon skipping across the human dystrophin gene transcript.
Mol Ther 2007; 15: 1288–1296.
31 Fujita E, Kouroku Y, Isoai A et al: Two endoplasmic reticulum-associated degra-
dation (ERAD) systems for the novel variant of the mutant dysferlin: ubiquitin/
proteasome ERAD(I) and autophagy/lysosome ERAD(II). Hum Mol Genet 2007; 16:
618–629.
This work is licensed under the Creative Commons
Attribution-NonCommercial-No Derivative Works
3.0 Unported License. To view a copy of this license, visit http://
creativecommons.org/licenses/by-nc-nd/3.0/
Exon skipping for dysferlinopathies?
AA a r t s m a - R u set al
894
European Journal of Human Genetics